Synergistic Effect of Stromal Vascular Fraction and Lymph Node Transfer in a Rabbit Hindlimb Model.
Lee J., Kim J., Cheon JH., Lee HC., Chung JH., Yoon ES.
Animal Study, published in Tissue Eng Regen Med (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Tissue Eng Regen Med (2025)
- Country
- Korea (South)
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 40515932
- PMCID
- PMC12297188
- DOI
- 10.1007/s13770-025-00728-7
- Citations
- 1
Abstract (original English)
Background Adipose-derived stem cells (ADSCs) promote lymphangiogenesis, though their integration with vascularized lymph node transfer (VLNT) is not well-explored. Unlike ADSCs, the stromal vascular fraction (SVF) can be obtained intraoperatively without the need for cell culture, making it ideal for incorporation into VLNT in a single-stage surgical procedure. This study evaluates the impacts of combined VLNT and SVF therapy using a rabbit hindlimb model. Method New Zealand white rabbits were divided into four groups: control, VLNT only, SVF only, and combined VLNT plus SVF. The VLNT procedure involved transferring a pedicled lymph node flap, while the SVF was harvested and injected into the perinodal tissue. Postoperative assessments included measuring edema volume, performing ICG lymphography, conducting histological analysis, and measuring VEGF-C and LYVE-1 expression. Results Initial increases in hindlimb edema volume were noted, but a significant decrease occurred by week 4, particularly in the VLNT group and VLNT plus SVF group compared to the control group. Histological evaluations indicated that the combined treatment group preserved superior structural integrity of the lymph nodes, with a decreased proportion of fibroadipose tissue compared to the VLNT-only group. Elevated VEGF-C expression was observed in the SVF-treated groups, as confirmed by both RT-PCR and ELISA
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.